Nimbex

Nimbex is a brand name of cisatracurium, approved by the FDA in the following formulation(s):

NIMBEX (cisatracurium besylate - injectable; injection)

• 
  Manufacturer: ABBOTT
  
  Approval date: December 15, 1995
  
  Strength(s): EQ 2MG BASE/ML ^[RLD][AP]

Has a generic version of Nimbex been approved?

A generic version of Nimbex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Nimbex and have been approved by the FDA:

cisatracurium besylate injectable; injection

• 
  Manufacturer: SANDOZ INC
  
  Approval date: February 3, 2012
  
  Strength(s): EQ 2MG BASE/ML ^[AP]

CISATRACURIUM BESYLATE PRESERVATIVE FREE (cisatracurium besylate injectable; injection)

• 
  Manufacturer: SANDOZ INC
  
  Approval date: February 3, 2012
  
  Strength(s): EQ 2MG BASE/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nimbex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Neuromuscular blocking agents
  Patent 5,453,510
  Issued: September 26, 1995
  Inventor(s): Hill; Derek A. & Turner; Geoffrey L.
  Assignee(s): Burroughs Wellcome Co.
  1R-cis,1'R-cis isomer of a 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-veratrylisoquinolium) said, substantially free from other geometrical and optical isomers thereof. The 1R-cis,1'R-cis isomer has been found to have an advantageous combination of pharmacological properties, notably greater neuromuscular blocking potency, weaker histamine-releasing potency, and at equivalent levels of neuromuscular blockade, fewer potential adverse effects on the autonomic nervous system (sympathetic and parasympathetic blockage), in comparison with the known mixture of geometrical and optical isomers.
  
  Patent expiration dates:
  
  
  • September 26, 2012
    
    ✓ 
    Patent use: METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
  
  

See also...

• Nimbex Consumer Information (Wolters Kluwer)
• Nimbex Consumer Information (Cerner Multum)
• Nimbex AHFS DI Monographs (ASHP)
• Cisatracurium Consumer Information (Wolters Kluwer)
• Cisatracurium Consumer Information (Cerner Multum)
• Cisatracurium Besylate AHFS DI Monographs (ASHP)